Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (23750)	7/31/1998 12:16:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

<< That is if it gets approved. >> If Panretin Gel does not get approved, after Ligand delayed the NDA submission to the FDA, to provide more compelling data, it would be a killer to the stock, IMHO. Hmmmmm!? You made me think a little more about this......... Since the Panretin/Targretin science is so key to Ligand's success, this first approval would be a validation of their science, and might just give LGND a bigger shot in the arm than we might expect.